Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 6/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911523 | 0.80 | ESR1 (0.42) | ESR1ESR2PLAU | |
| SCHEMBL10915701 | 0.78 | ALDH1A1 (0.38) | HSD17B10CRHBPCRHR2CYP3A4ALDH1A1 | |
| SCHEMBL31026244 | 0.77 | BACE1 (0.35) | CRHBPCRHR2ARCYP1A2 | |
| SCHEMBL29241814 | 0.75 | CRHBP (0.31) | CRHBPCRHR2 | |
| SCHEMBL3565423 | 0.72 | ALDH1A1 (0.58) | CYP3A4HPGDCYP1A2ALDH1A1 | |
| SCHEMBL29241832 | 0.72 | SLC40A1 (0.31) | CYP1A2NQO2 | |
| SCHEMBL11060367 | 0.72 | NR4A2 (0.37) | HSD17B10CRHBPCRHR2CYP3A4HPGD | |
| SCHEMBL31058638 | 0.71 | HPGDS (0.37) | — | |
| SCHEMBL31026254 | 0.71 | HPGDS (0.37) | — | |
| SCHEMBL7935896 | 0.70 | CRHBP (0.38) | HSD17B10CRHBPCRHR2CYP3A4PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169675-B1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2018-09-19 | — | — | EP | disclosed |
| US-20170197938-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2017-07-13 | — | — | US | disclosed |
| US-20170197938-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2017-07-13 | — | — | US | disclosed |
| US-20170197938-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2017-07-13 | — | — | US | disclosed |
| EP-3169675-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016009066-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | ABIVAX (FR) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975034-A1 | A quinoline derivative for the treatment of inflammatory diseases and AIDS | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975034-A1 | A quinoline derivative for the treatment of inflammatory diseases and AIDS | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197938-A1 | A QUINOLINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND AIDS | IL17A, IL1B, IL1A | HSD17B10 756/4885CRHBP 4389/4885CRHR2 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.